Table 1. Characteristics of RTB-specific VHHs and mAbs used in this study.
| VHH/mAbs | GenBanka | Length (AA) | Verob | THP-1 Prec | THP-1 Postc | Protection |
| TFTB-1d | NA | NA | ND | ND | ND | – |
| 24B11d | NA | NA | 1.2 | 0.25 | 0.25 | + |
| RTB-B7 | KF746034 | 132 | 1.5 | 0.25 | 1.4 | – |
| RTB-D12 | KF746031 | 130 | – | – | 330 | – |
| RTB-D8 | KF746036 | 124 | – | – | 330 | – |
| RTA-G12 | KF746020 | 137 | ND | ND | ND | – |
a
GenBank accession numbers; bVero cytotoxicity assay performed as described in Materials and Methods; value shown are in nM; cPre-bound and post-bound THP-1 cytotoxicity assays performed in Materials and Methods; values shown are in nM. dAnti-RTB mAbs previously characterized in [26], [29]. Abbreviations: ND, not determined; NA, not applicable.